Vectibix
What Vectibix is used for
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): in first-line in combination with Folfox or Folfiri. in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Vectibix
- Active substance
- panitumumab
- Disease area
- Colorectal Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XC08
- Marketing authorisation holder
- Amgen Europe B.V.
- Authorised in the EU since
- 2007
Official information
In the USA
Same active substance: Vectibix
In India
- Panitumumab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vectibix used for?
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): in first-line in combination with Folfox or Folfiri. in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
What is the active substance in Vectibix?
Vectibix contains panitumumab.
Who makes Vectibix?
The EU marketing authorisation holder is Amgen Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU